Cottencin O, Regnaut N, Thévenon-Gignac C, Thomas P, Goudemand M, Debruille C, Robert H
CHRU Lille, Université de Lille II, Service de Psychiatrie générale.
Encephale. 1995 Mar-Apr;21(2):141-5.
The current practices concerning psychotropic drugs use plasma levels for the therapeutic adaptation and for the prevention of overdose and side effects. We observed, among two patients treated with constant dosages of carbamazepine (CBZ), that the addition of fluvoxamine (FLV) has increased significantly plasma levels of CBZ. The first patient, suffering of an affective bipolar trouble (ICD-10), was hospitalized for major depression. His admission treatment was CBZ (800 mg/day) and cyamemazine (75 mg/day). The introduction of the FLV (200 mg/day) was justified by the symptomatology. Then, plasma levels of CBZ increased progressively. No clinic or biological side effect was observed. Rapidly, CBZ oral dosages were decreased, but the plasma levels of CBZ reached the therapeutic window only when the FLV prescription was definitively stopped. The other patient was hospitalized for an acute exacerbation of a paranoiac disorder. He was treated with haloperidol for this episode. For five years, he received CBZ for neuralgia of the Trigeminus. The emergence of a depressive disorder justified a FLV treatment. From the introduction of FLV, plasma levels of CBZ were significantly increased. The reduction, then the stop of the FLV treatment, has allowed the standardization of plasma concentrations of CBZ. Three similar studies were found in the literature. The danger of this interaction was notified in two studies (one case each). Furthermore, in the third study (three cases) was put forward the hypothesis of a new therapeutic pathway. this hypothesis was suggested by the fact that these two medications were proposed independently to treat impulsive behaviors.(ABSTRACT TRUNCATED AT 250 WORDS)
目前使用精神药物时会检测血药浓度,以调整治疗方案、预防用药过量及副作用。我们观察到,在两名接受恒定剂量卡马西平(CBZ)治疗的患者中,加用氟伏沙明(FLV)后,CBZ的血药浓度显著升高。第一名患者患有双相情感障碍(ICD - 10),因重度抑郁住院。其入院治疗药物为CBZ(800毫克/天)和氰美马嗪(75毫克/天)。根据症状加用FLV(200毫克/天)。随后,CBZ的血药浓度逐渐升高,未观察到临床或生物学副作用。很快,CBZ的口服剂量减少,但直到最终停用FLV,CBZ的血药浓度才达到治疗窗。另一名患者因偏执性障碍急性加重住院,此次发作接受氟哌啶醇治疗。五年来,他因三叉神经痛接受CBZ治疗。出现抑郁症后开始使用FLV治疗。自加用FLV后,CBZ的血药浓度显著升高。减少并停用FLV治疗后,CBZ的血药浓度恢复正常。文献中还发现三项类似研究。两项研究(各1例)提示了这种相互作用的风险。此外,第三项研究(3例)提出了一种新治疗途径的假设。这一假设基于这两种药物最初是分别用于治疗冲动行为这一事实。(摘要截断于250字)